Breadcrumb

Dr. Byram Ozer

Byram H. Ozer, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Neuro-Oncology Branch

RESEARCH SUMMARY

Dr. Ozer is a neuro-oncologist who cares for patients with rare brain and spine tumors as part of the NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) program at the NCI Center for Cancer Research's Neuro-Oncology Branch (NOB). His interests encompass clinical research—designing clinical trial protocols to test new therapeutics and novel combinations—as well as translational research that uses scientific advancements to understand the cellular processes underlying tumor development and progression. These interests span disciplines, and Dr. Ozer works with diverse groups of clinical and scientific collaborators in neurosurgery, neuropathology, radiation oncology, neuro-radiology, and genetic counseling.

> Explore the NOB's Research Programs

Areas of Expertise

1) Meningioma 2) Rare central nervous system tumors 3) Clinical trials 4) Translational research

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Publications

High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes

Ye X, Schreck KC, Ozer BH, Grossman SA
Expert Review of Anticancer Therapy. 22(3): 275-287, 2022. [ Journal Article ]

TSC2 alterations in anaplastic ependymoma progression to ependymosarcoma

Pugudas E, Chen L, Weingart JD, Orr B, Ozer BH, Holdhoff M, Rodriguez FJ
Clinical Neuropathology. 39(4): 179-187, 2020. [ Journal Article ]

SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation

Liu F, Cox CD, Chowdhury R, Dovek L; Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphus PL, Yong W, Cloughesy T, Lai A
Journal of Neuro-Oncology. 142(3): 423-434, 2019. [ Journal Article ]

D-2-Hydroxyglutarate is necessary and sufficient for isocitrate dehydrogenase 1 mutant-induced MIR148A promoter methylation

Li T, Cox CD, Ozer BH, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A
Molecular Cancer Research. 16(6): 947-960, 2018. [ Journal Article ]